Purging of human breast cancer cells from stem cell products with an adenovirus containing p53

Manabu Hirai, Linda S. Kelsey, Mei Vaillancourt, Daniel C. Maneval, Tsutomu Watanabe, James E Talmadge

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Tumor cell contamination of stem cell products can contribute to tumor relapse following high-dose chemotherapy and stem cell rescue. Numerous techniques have been used to remove the tumor cells from stem cell products with the objective of prolonging relapse-free survival. However, to date these techniques have been relatively ineffectual and/or toxic to hematopoietic stem and progenitor cells. The differential infectivity of adenovirus (Adv) vectors for breast cancer cells, compared with hematopoietic cells, has suggested that Adv-p53 might provide an effective purging strategy. To facilitate the use of Adv-p53 as a clinical strategy, we undertook studies to determine the parameters necessary for optimal stem cell product purging. The parameters studied were the particle number to nucleated cell ratio, the duration of coincubation, the incubation volume, and the presence or absence of hematopoietic progenitor cells. We have found that these parameters are interdependent and conclude that a 4-hour coincubation with an Adv-p53 particle to nucleated cell ratio of 2000:1 with 2 x 108 nucleated cells/mL is optimal for tumor cell purging. Furthermore, this appeared to be a safe procedure, with total loss of clonogenic growth of breast cancer cells as well as no significant effect on progenitor cell function as determined by granulocyte-macrophage colony-forming unit assays.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalCancer Gene Therapy
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2000

Fingerprint

Adenoviridae
Stem Cells
Breast Neoplasms
Hematopoietic Stem Cells
Neoplasms
Colony-Forming Units Assay
Recurrence
Granulocyte-Macrophage Progenitor Cells
Poisons
Drug Therapy
Survival
Growth

Keywords

  • Adenovirus
  • Breast cancer
  • Clonogenic growth
  • Purging
  • p53

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Purging of human breast cancer cells from stem cell products with an adenovirus containing p53. / Hirai, Manabu; Kelsey, Linda S.; Vaillancourt, Mei; Maneval, Daniel C.; Watanabe, Tsutomu; Talmadge, James E.

In: Cancer Gene Therapy, Vol. 7, No. 2, 01.01.2000, p. 197-206.

Research output: Contribution to journalArticle

Hirai, Manabu ; Kelsey, Linda S. ; Vaillancourt, Mei ; Maneval, Daniel C. ; Watanabe, Tsutomu ; Talmadge, James E. / Purging of human breast cancer cells from stem cell products with an adenovirus containing p53. In: Cancer Gene Therapy. 2000 ; Vol. 7, No. 2. pp. 197-206.
@article{2c5119afab1a4388a6f99204e45ed518,
title = "Purging of human breast cancer cells from stem cell products with an adenovirus containing p53",
abstract = "Tumor cell contamination of stem cell products can contribute to tumor relapse following high-dose chemotherapy and stem cell rescue. Numerous techniques have been used to remove the tumor cells from stem cell products with the objective of prolonging relapse-free survival. However, to date these techniques have been relatively ineffectual and/or toxic to hematopoietic stem and progenitor cells. The differential infectivity of adenovirus (Adv) vectors for breast cancer cells, compared with hematopoietic cells, has suggested that Adv-p53 might provide an effective purging strategy. To facilitate the use of Adv-p53 as a clinical strategy, we undertook studies to determine the parameters necessary for optimal stem cell product purging. The parameters studied were the particle number to nucleated cell ratio, the duration of coincubation, the incubation volume, and the presence or absence of hematopoietic progenitor cells. We have found that these parameters are interdependent and conclude that a 4-hour coincubation with an Adv-p53 particle to nucleated cell ratio of 2000:1 with 2 x 108 nucleated cells/mL is optimal for tumor cell purging. Furthermore, this appeared to be a safe procedure, with total loss of clonogenic growth of breast cancer cells as well as no significant effect on progenitor cell function as determined by granulocyte-macrophage colony-forming unit assays.",
keywords = "Adenovirus, Breast cancer, Clonogenic growth, Purging, p53",
author = "Manabu Hirai and Kelsey, {Linda S.} and Mei Vaillancourt and Maneval, {Daniel C.} and Tsutomu Watanabe and Talmadge, {James E}",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.cgt.7700088",
language = "English (US)",
volume = "7",
pages = "197--206",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Purging of human breast cancer cells from stem cell products with an adenovirus containing p53

AU - Hirai, Manabu

AU - Kelsey, Linda S.

AU - Vaillancourt, Mei

AU - Maneval, Daniel C.

AU - Watanabe, Tsutomu

AU - Talmadge, James E

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Tumor cell contamination of stem cell products can contribute to tumor relapse following high-dose chemotherapy and stem cell rescue. Numerous techniques have been used to remove the tumor cells from stem cell products with the objective of prolonging relapse-free survival. However, to date these techniques have been relatively ineffectual and/or toxic to hematopoietic stem and progenitor cells. The differential infectivity of adenovirus (Adv) vectors for breast cancer cells, compared with hematopoietic cells, has suggested that Adv-p53 might provide an effective purging strategy. To facilitate the use of Adv-p53 as a clinical strategy, we undertook studies to determine the parameters necessary for optimal stem cell product purging. The parameters studied were the particle number to nucleated cell ratio, the duration of coincubation, the incubation volume, and the presence or absence of hematopoietic progenitor cells. We have found that these parameters are interdependent and conclude that a 4-hour coincubation with an Adv-p53 particle to nucleated cell ratio of 2000:1 with 2 x 108 nucleated cells/mL is optimal for tumor cell purging. Furthermore, this appeared to be a safe procedure, with total loss of clonogenic growth of breast cancer cells as well as no significant effect on progenitor cell function as determined by granulocyte-macrophage colony-forming unit assays.

AB - Tumor cell contamination of stem cell products can contribute to tumor relapse following high-dose chemotherapy and stem cell rescue. Numerous techniques have been used to remove the tumor cells from stem cell products with the objective of prolonging relapse-free survival. However, to date these techniques have been relatively ineffectual and/or toxic to hematopoietic stem and progenitor cells. The differential infectivity of adenovirus (Adv) vectors for breast cancer cells, compared with hematopoietic cells, has suggested that Adv-p53 might provide an effective purging strategy. To facilitate the use of Adv-p53 as a clinical strategy, we undertook studies to determine the parameters necessary for optimal stem cell product purging. The parameters studied were the particle number to nucleated cell ratio, the duration of coincubation, the incubation volume, and the presence or absence of hematopoietic progenitor cells. We have found that these parameters are interdependent and conclude that a 4-hour coincubation with an Adv-p53 particle to nucleated cell ratio of 2000:1 with 2 x 108 nucleated cells/mL is optimal for tumor cell purging. Furthermore, this appeared to be a safe procedure, with total loss of clonogenic growth of breast cancer cells as well as no significant effect on progenitor cell function as determined by granulocyte-macrophage colony-forming unit assays.

KW - Adenovirus

KW - Breast cancer

KW - Clonogenic growth

KW - Purging

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0034117721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034117721&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700088

DO - 10.1038/sj.cgt.7700088

M3 - Article

C2 - 10770627

AN - SCOPUS:0034117721

VL - 7

SP - 197

EP - 206

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 2

ER -